Even as Revlimid's star fades, Bristol Myers' core offerings have reached a 'critical mass,' CEO says

Even as Revlimid generics chip away at Bristol Myers Squibb's top line, the company remains confident it can shepherd its roster of new drugs toward more than $25 billion in revenues by 2029, executives said on a conference call Wednesday.